Oncostellae has started today a first-in-human study of OST-122, its novel, gut-restricted Jak3/Tyk2 inhibitor that is being developed for the local treatment of inflammatory and autoimmune diseases in the gastrointestinal tract, such as Ulcerative Colitis and Crohn’s Disease. The safety, tolerability and pharmacokinetic properties of OST-122 will be assessed in a randomized, double-blind, placebo-controlled Phase I clinical trial in healthy volunteers at the Hospital Sant Pau of Barcelona. Results are expected by the end of the year (single ascending doses) and in spring 2019 (multiple ascending doses).